MCID: CRN036
MIFTS: 52

Craniopharyngioma malady

Categories: Rare diseases, Neuronal diseases, Endocrine diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Craniopharyngioma

About this section
Sources:
11Disease Ontology, 13DISEASES, 31ICD10 via Orphanet, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Craniopharyngioma:

Name: Craniopharyngioma 11 48 54 50 39 13 68
Dysodontogenic Epithelial Tumor 48
Craniopharyngeal Duct Tumor 48
 
Neoplasm of Rathke's Pouch 11
Adamantinomatous Tumor 48
Rathke's Pouch Tumor 48

Characteristics:

Orphanet epidemiological data:

54
craniopharyngioma:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (United States),1-9/1000000 (Sweden); Age of onset: All ages

Classifications:



External Ids:

Disease Ontology11 DOID:3840
MeSH39 D003397
NCIt45 C2964
Orphanet54 ORPHA54595
SNOMED-CT62 189179009, 40009002
ICD10 via Orphanet31 D44.4
MESH via Orphanet40 D003397
UMLS via Orphanet69 C0010276

Summaries for Craniopharyngioma

About this section
NIH Rare Diseases:48 Craniopharyngioma is a slow-growing benign tumor that develops near the pituitary gland (a small endocrine gland at the base of the brain) and the hypothalamus (a small cone-shaped organ connected to the pituitary gland by nerves). This tumor most commonly affects children between 5 and 10 years of age; however, adults can sometimes be affected. Although craniopharyngiomas are benign (not cancerous), they may grow and press on nearby parts of the brain, causing symptoms including vision changes, slow growth, headaches, nausea and vomiting, loss of balance, and hearing loss. The cause of these tumors is not well understood; however, researchers suspect that they begin during the early stages of development in pregnancy (embryogenesis) and may result from metaplasia (abnormal transformation of cells). Treatment for craniopharyngioma varies and may include: surgery to remove the tumor, radiation therapy, chemotherapy, and biologic therapy.  Last updated: 8/4/2016

MalaCards based summary: Craniopharyngioma, also known as dysodontogenic epithelial tumor, is related to bardet-biedl syndrome and diabetes insipidus, and has symptoms including visual disturbance An important gene associated with Craniopharyngioma is CTNNB1 (Catenin Beta 1), and among its related pathways are Glioblastoma Multiforme and Corticotropin-releasing hormone. Affiliated tissues include brain, pituitary and bone, and related mouse phenotypes are Increased Nanog expression and hearing/vestibular/ear.

Wikipedia:71 Craniopharyngioma is a type of brain tumor derived from pituitary gland embryonic tissue, that occurs... more...

Related Diseases for Craniopharyngioma

About this section

Diseases related to Craniopharyngioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 157)
idRelated DiseaseScoreTop Affiliating Genes
1bardet-biedl syndrome28.8INS, PRL, TRH
2diabetes insipidus27.9GNRH1, IGF1, INS, POU1F1, PRL, PROP1
3papillary craniopharyngioma12.1
4adamantinous craniopharyngioma12.0
5cystadenoma10.8
6hemoglobin d disease10.5CTNNB1, KRT14
7split hand split foot malformation autosomal recessive10.5BRAF, MKI67
8mucinous stomach adenocarcinoma10.5CTNNB1, MKI67
9amelogenesis imperfecta local hypoplastic10.5KRT14, MKI67
10seizures mental retardation hair dysplasia10.5IGF1, INS
11bone squamous cell carcinoma10.5CTNNB1, KRT14, KRT8
12oligoastrocytoma10.4KRT14, KRT8
13mental retardation, autosomal recessive 4910.3KRT14, KRT8
14primary fanconi syndrome10.3POU1F1, PROP1
15tricuspid valve agenesis10.3POU1F1, PROP1
16cetp-related hyperalphalipoproteinemia10.3GNRH1, IGF1
17bladder clear cell adenocarcinoma10.3KRT14, KRT8
18thbd-related atypical hemolytic-uremic syndrome10.3IGF1, INS
19obesity10.3
20diarrhea 3, secretory sodium, congenital, syndromic10.2IGF1, INS
21gestational choriocarcinoma10.2GHRL, IGF1, INS
22angiomatous meningioma10.2GHRL, IGF1, INS
23seminal vesicle tumor10.2CTNNB1, MMP20
24adenoma10.1
25pituitary adenoma10.1
26lymphadenitis10.0GNRH1, INS, TRH
27genetic lipodystrophy9.9PRL, TRH
28hypertelorism, preauricular sinus, punctal pits, and deafness9.9INS, TRH
29immune system organ benign neoplasm9.9CTNNB1, IGF1, PRL
30fibrosclerosis of breast9.9IGF1, PRL
31mobitz type ii atrioventricular block9.9GNRH1, PRL
32benign prostate phyllodes tumor9.9GNRH1, PRL
33postpartum depression9.9INS, PRL
34aneurysm or dilatation of ascending aorta9.9PRL, TRH
35hemiplegia alterans9.9INS, PRL
36lipid-rich carcinoma9.9GNRH1, PRL
37cerebritis9.9
38male reproductive organ cancer9.9BRAF, CTNNB1, KRT14, KRT8, SP7
39meningitis9.8
40dysthymic disorder9.8GHRL, INS, PRL
41acatalasemia9.8GHRL, IGF1, PRL
42astrocytoma9.8
43hypopituitarism9.8
44diencephalic syndrome9.8
45cardiovascular organ benign neoplasm9.8IGF1, PRL, TRH
46muscular dystrophy-dystroglycanopathy , type a, 29.8BRAF, CTNNB1, GNRH1, IGF1, MKI67
47skull base neoplasm9.8IGF1, PRL, TRH
48lung cancer susceptibility 29.7IGF1, INS, PRL
49prolactin producing pituitary tumor9.7GNRH1, IGF1, PRL
50neuroblastoma9.7

Graphical network of the top 20 diseases related to Craniopharyngioma:



Diseases related to craniopharyngioma

Symptoms & Phenotypes for Craniopharyngioma

About this section

UMLS symptoms related to Craniopharyngioma:


visual disturbance

GenomeRNAi Phenotypes related to Craniopharyngioma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00371-A-39.4MCM6, MKI67, PROP1, SP7

MGI Mouse Phenotypes related to Craniopharyngioma according to GeneCards Suite gene sharing:

41 (show all 12)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053779.6BRAF, CTNNB1, IGF1, KRT14, POU1F1
2MP:00053709.5BRAF, CTNNB1, GNRH1, INS, KRT8, PRL
3MP:00053819.3BRAF, CTNNB1, GHRL, GNRH1, INS, KRT14
4MP:00107719.3BRAF, CTNNB1, GNRH1, IGF1, INS, KRT14
5MP:00020068.9BRAF, CTNNB1, GNRH1, IGF1, KRT14, MCM6
6MP:00053878.2BRAF, CTNNB1, GNRH1, IGF1, INS, KRT14
7MP:00053977.9BRAF, CTNNB1, GNRH1, IGF1, INS, KRT14
8MP:00036317.9BRAF, CTNNB1, GNRH1, IGF1, INS, POU1F1
9MP:00053797.4BRAF, CTNNB1, GHRL, GNRH1, IGF1, INS
10MP:00053897.0BRAF, CTNNB1, GNRH1, IGF1, INS, KRT14
11MP:00053786.6BRAF, CTNNB1, GNRH1, IGF1, INS, KRT14
12MP:00053766.6BRAF, CTNNB1, GHRL, GNRH1, IGF1, INS

Drugs & Therapeutics for Craniopharyngioma

About this section

Drugs for Craniopharyngioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 190)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Hydrocortisoneapproved, vet_approvedPhase 464050-23-75754, 657311
Synonyms:
(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Cetacort
Chronocort
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
Evacort
Ficortril
Fiocortril
Flexicort
Foille Insetti
Genacort
Genacort (lotion)
Glycort
Gyno-Cortisone
H 4001
H-Cort
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
 
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Heb Cort
Heb-Cort
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone Acetate
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone Sodium Phosphate
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall'S compound F
Kendall's compound F
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Lopac0_000594
Lubricort
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Medicort
Meusicort
Mildison
Milliderm
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Neo-Cort-Dome
Neo-Cortef
Neosporin-H Ear
Nogenic HC
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pediotic Suspension
Penecort
Permicort
Polcort H
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein'S substance M
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Sanatison
Scalp-Cort
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral Hydrocort
Tarcortin
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone
2
Prednisoneapproved, vet_approvedPhase 4135953-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
3
butyric acidexperimentalPhase 4363107-92-6264
Synonyms:
1-Butanoate
1-Butanoic acid
1-Butyrate
1-Butyric acid
1-Propanecarboxylate
1-Propanecarboxylic acid
Butanate
Butanic acid
Butanoate
Butanoic acid
Buttersaeure
Butyrate
 
Butyric acid
Ethylacetate
Ethylacetic acid
Honey robber
Kyselina maselna
N-Butanoate
N-Butanoic acid
N-Butyrate
N-Butyric acid
Propanecarboxylate
Propanecarboxylic acid
Propylformate
Propylformic acid
4Hydrocortisone 17-butyrate 21-propionatePhase 4640
5Hydrocortisone acetatePhase 4640
6Hydrocortisone-17-butyratePhase 4318
7AnestheticsPhase 4, Phase 39001
8Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 112767
9Antineoplastic Agents, HormonalPhase 4, Phase 2, Phase 15407
10Anti-Inflammatory AgentsPhase 4, Phase 110355
11glucocorticoidsPhase 4, Phase 14920
12Cortisol succinatePhase 4640
13HormonesPhase 4, Phase 3, Phase 2, Phase 113979
14Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 112778
15
Fentanylapproved, illicit, investigational, vet_approvedPhase 3773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
16
DonepezilapprovedPhase 3, Phase 2280120014-06-43152
Synonyms:
( inverted exclamation markA)-E 2020
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
120014-06-4
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC-6969
AC1L1FAE
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
 
Donepezil
Donepezil (INN)
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum5_001662
Spectrum_001664
TL8000531
UNII-8SSC91326P
17
Exenatideapproved, investigationalPhase 3, Phase 2, Phase 1289141758-74-915991534
Synonyms:
141732-76-5
141758-74-9
286014-72-0
335149-21-8
AC 2993
AC 2993 LAR
AC 2993A
AC-2993
AC002993
AC2993
AC2993a
Bydureon
Byetta
 
C074031
CHEBI:490990
CHEMBL414357
Ex4 peptide
Exenatide
Exenatide Synthetic
Exenatide synthetic
Exendin 4
Exendin 4 (Heloderma suspectum)
Exendin-4
Extendin-4
LY2148568
Synthetic exendin-4
UNII-9P1872D4OL
18
DiazoxideapprovedPhase 3, Phase 222364-98-73019
Synonyms:
2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
364-98-7
7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide
7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido
7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]
7-chloro-3-methyl-4H-1
AC1L1EZN
Aroglycem
BPBio1_000016
BRD-K73109821-001-05-2
BSPBio_000014
BSPBio_001307
BSPBio_002290
Bio1_000036
Bio1_000525
Bio1_001014
Bio2_000027
Bio2_000507
C06949
C8H7ClN2O2S
CAS-364-98-7
CBiol_001750
CHEBI:4495
CHEMBL181
CID3019
CPD000058392
D 9035
D00294
D003981
D9035_SIGMA
DB01119
Diazossido
Diazossido [DCIT]
Diazossido [Italian]
Diazoxide
Diazoxide (JAN/USP/INN)
Diazoxide [USAN:INN:BAN]
Diazoxido
Diazoxido [INN-Spanish]
Diazoxidum
Diazoxidum [INN-Latin]
Dizoxide
EINECS 206-668-1
EU-0100404
Eudemine
HMS1361B09
HMS1568A16
HMS1791B09
HMS1922L22
HMS1989B09
HMS2051P20
HMS2089L04
HMS2093N12
Hyperstat
Hyperstat (TN)
Hypertonalum
I06-2041
 
IDI1_033777
KBio2_000027
KBio2_002595
KBio2_005163
KBio3_000053
KBio3_000054
KBio3_001510
KBioGR_000027
KBioGR_001776
KBioSS_000027
LS-40410
Lopac-D-9035
Lopac0_000404
MLS000028459
MLS001076071
MolPort-003-666-772
MolPort-003-941-186
Mutabase
NCGC00015380-01
NCGC00015380-02
NCGC00015380-03
NCGC00015380-05
NCGC00015380-12
NCGC00024907-01
NCGC00024907-02
NCGC00024907-03
NCGC00024907-04
NCGC00024907-05
NCGC00024907-06
NCGC00024907-07
NCGC00024907-08
NSC 64198
NSC 76130
NSC-64198
NSC64198
NSC76130
Prestwick0_000087
Prestwick1_000087
Prestwick2_000087
Prestwick3_000087
Prestwick_163
Proglicem
Proglycem
SAM001246872
SMR000058392
SPBio_001953
SPECTRUM2300206
SRG 95213
SRG-95213
Sch 6783
Sch-6783
Spectrum3_000735
Spectrum4_001248
Tocris-0964
UNII-O5CB12L4FN
VU0239714-6
ZINC03872277
diazoxide
nchembio.150-comp49
nchembio.476-comp10
19
Dexamethasoneapproved, investigational, vet_approvedPhase 3, Phase 1208450-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
20
CisplatinapprovedPhase 3269015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
21
OndansetronapprovedPhase 330999614-02-54595
Synonyms:
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
99614-01-4 (mono-hydrochloride)
99614-02-5
AB00373674
AC1L1IIM
AKOS000599484
Apo-ondansetron
BAS 00717177
BPBio1_001118
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CBDivE_008994
CHEMBL46
CID4595
CPD001307702
D00456
DB00904
DESMETHYLONDANSETRON
GR 38032
GR 38032X
GR-38032F
GR38032F
HMS2090H16
I06-0687
I06-1329
 
L000456
LS-172305
LS-51878
MolPort-001-944-253
NCI60_022780
Novo-ondansetron
Ondansetron
Ondansetron (JAN/USP/INN)
Ondansetron [USAN:INN:BAN]
Ondansetron, (+,-)-Isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
Ratio-ondansetron
SAM002589958
SN-307
SPBio_002938
STK370548
STOCK4S-10990
Sandoz ondansetron
TL8006071
TimTec1_001750
UNII-4AF302ESOS
ZOFRAN IN PLASTIC CONTAINER
Zofran
Zofran ODT
Zofran ODT (TN)
Zofran odt
Zophren
Zudan
ondansetron
ondansetron (Zofran)
22
Granisetronapproved, investigationalPhase 371109889-09-03510
Synonyms:
1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide
109889-09-0
AC1NR4P1
APF530
BIDD:GT0272
BRL-43694
C07023
CHEMBL519643
CID5284566
D04370
 
Granisetron (USAN/INN)
Granisetron HCl
Granisetron base
Granisetron hydrochloride
Granisetronum [INN-Latin]
HMS2089P14
Kytril
MolPort-005-943-366
granisetron
granisetronum
granisetrón
granisétron
23Liver ExtractsPhase 3, Phase 1, Phase 23868
24Neurotransmitter AgentsPhase 3, Phase 2, Phase 117734
25Cholinesterase InhibitorsPhase 3, Phase 2570
26Nootropic AgentsPhase 3, Phase 2701
27Gastrointestinal AgentsPhase 3, Phase 2, Phase 18109
28Hypoglycemic AgentsPhase 3, Phase 2, Phase 15733
29IncretinsPhase 3, Phase 2, Phase 11537
30Central Nervous System DepressantsPhase 3, Phase 112806
31Cholinergic AgentsPhase 3, Phase 23846
32Anesthetics, GeneralPhase 32787
33Analgesics, OpioidPhase 33091
34AnalgesicsPhase 311287
35Vasodilator AgentsPhase 3, Phase 23438
36Anesthetics, IntravenousPhase 32406
37Peripheral Nervous System AgentsPhase 3, Phase 122776
38pancreatic polypeptidePhase 3, Phase 120
39NarcoticsPhase 33486
40Antihypertensive AgentsPhase 3, Phase 24095
41Adjuvants, AnesthesiaPhase 31588
42Glucagon-Like Peptide 1Phase 3694
43glucagonPhase 3462
44Dexamethasone acetatePhase 3, Phase 120841177-87-3
45EmeticsPhase 3175
46Autonomic AgentsPhase 3, Phase 19774
47Dexamethasone 21-phosphatePhase 3, Phase 12084
48BB 1101Phase 3, Phase 12084
49AntiemeticsPhase 3, Phase 13888
50ColaNutraceuticalPhase 3, Phase 11881

Interventional clinical trials:

(show top 50)    (show all 100)
idNameStatusNCT IDPhase
1Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar LesionsUnknown statusNCT02190994Phase 4
2Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary LesionsCompletedNCT00306683Phase 3
3Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
4Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain TumorsCompletedNCT00369785Phase 3
5Energy Balance in Craniopharyngioma-related Hypothalamic ObesityRecruitingNCT02664441Phase 3
690Yttrium Colloid for the Treatment of Cystic Sellar/Parasellar TumorsRecruitingNCT02081768Phase 3
7SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain TumorsActive, not recruitingNCT00517959Phase 3
8Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic ChemotherapyActive, not recruitingNCT01346267Phase 3
9Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma TherapyNot yet recruitingNCT02860923Phase 3
10Antineoplaston Therapy in Treating Children With Primary Malignant Brain TumorsUnknown statusNCT00003476Phase 2
11Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide TherapyCompletedNCT00892073Phase 2
12Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain TumorCompletedNCT01484873Phase 2
13A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side EffectsCompletedNCT00187226Phase 2
14An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic InjuryCompletedNCT02063295Phase 2
15Irinotecan in Treating Children With Refractory Solid TumorsCompletedNCT00004078Phase 2
16Antineoplaston Therapy in Treating Children With Brain TumorsCompletedNCT00003458Phase 2
17Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid TumorsCompletedNCT00005952Phase 1, Phase 2
18Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain TumorsCompletedNCT00003461Phase 1, Phase 2
19Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00006102Phase 2
20Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS TumorsCompletedNCT00005955Phase 2
21Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain TumorCompletedNCT00070161Phase 2
22Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer TreatmentCompletedNCT00066248Phase 2
23A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical ResectionRecruitingNCT02792582Phase 2
24Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By SurgeryRecruitingNCT01964300Phase 2
25Intranasal Oxytocin in Hypothalamic ObesityRecruitingNCT02849743Phase 2
26Photodynamic Therapy (PDT) For Recurrent High Grade GliomasRecruitingNCT01966809Phase 2
27A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical ResectionActive, not recruitingNCT01419067Phase 2
28Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma)Active, not recruitingNCT02842723Phase 2
29Effects of Exenatide on Hypothalamic ObesityActive, not recruitingNCT01061775Phase 1, Phase 2
30Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaActive, not recruitingNCT00939770Phase 1, Phase 2
31Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid TumorsActive, not recruitingNCT00788125Phase 1, Phase 2
32Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer TherapyTerminatedNCT01348607Phase 2
33Tumor Classification and Its Application in Surgical Treatment of CraniopharyngiomaUnknown statusNCT00949156Phase 1
34Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain TumorsUnknown statusNCT00002647Phase 1
35Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid TumorsUnknown statusNCT00007813Phase 1
36Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem GliomaUnknown statusNCT00360854Phase 1
37Stereotactic Radiosurgery in Treating Patients With Brain TumorsCompletedNCT00019578Phase 1
38Cilengitide in Treating Children With Refractory Primary Brain TumorsCompletedNCT00063973Phase 1
39Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain TumorsCompletedNCT00052780Phase 1
40ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS TumorsCompletedNCT00946335Phase 1
41Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LymphomaCompletedNCT00363272Phase 1
42Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS TumorsCompletedNCT00100880Phase 1
43FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
44RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT01119599Phase 1
45Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsCompletedNCT01076530Phase 1
46Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
47SCH 66336 in Treating Children With Recurrent or Progressive Brain TumorsCompletedNCT00015899Phase 1
48O6-benzylguanine and Carmustine in Treating Children With Refractory CNS TumorsCompletedNCT00003765Phase 1
49Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to TherapyCompletedNCT00030108Phase 1
50Temozolomide and O6-benzylguanine in Treating Children With Solid TumorsCompletedNCT00020150Phase 1

Search NIH Clinical Center for Craniopharyngioma


Cochrane evidence based reviews: craniopharyngioma

Genetic Tests for Craniopharyngioma

About this section

Anatomical Context for Craniopharyngioma

About this section

MalaCards organs/tissues related to Craniopharyngioma:

36
Brain, Pituitary, Bone, T cells, Liver, Spinal cord, Endothelial

Publications for Craniopharyngioma

About this section

Articles related to Craniopharyngioma:

(show top 50)    (show all 715)
idTitleAuthorsYear
1
Malignant Transformation of Craniopharyngioma without Radiation Therapy: Case Report and Review of the Literature. (28061501)
2017
2
Norman M. Dott, master of hypothalamic craniopharyngioma surgery: the decisive mentoring of Harvey Cushing and Percival Bailey at Peter Bent Brigham Hospital. (28059655)
2017
3
The neuroendocrine sequelae of paediatric craniopharyngioma: a 40 year meta-data analysis of 185 cases from three UK centres. (28073908)
2017
4
Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma. (28069929)
2017
5
Letter to the Editor: Recurrent or residual craniopharyngioma: management options. (28009237)
2016
6
Simultaneous Transventricular-Orbitocranial Resection of Large Suprasellar Craniopharyngioma as Inspired by Jackson's Maneuver from 1863. (27054052)
2016
7
Evaluation of Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer in Primary Craniopharyngioma by Fourier-Domain Optical Coherence Tomography. (27372909)
2016
8
EpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathke's cleft cysts. (27431859)
2016
9
Expanded Endonasal Endoscopic Approach for Resection of an Infrasellar Craniopharyngioma. (27554305)
2016
10
Fenestrated optic nerve in craniopharyngioma. (27366261)
2016
11
Craniopharyngioma recurrence: the impact of tumor topography. (27494816)
2016
12
Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma. (27640198)
2016
13
Fusiform dilatation of the internal carotid artery in childhood-onset craniopharyngioma: multicenter study on incidence and long-term outcome. (27125511)
2016
14
Removal of craniopharyngioma via fronto-basal interhemispheric approach. (27347116)
2016
15
Visualization of 90Yttrium Colloid Within a Cystic Craniopharyngioma Using PET/CT/MRI Fusion. (27846921)
2016
16
Periostin activates pathways involved in epithelial-mesenchymal transition in adamantinomatous craniopharyngioma. (26723972)
2016
17
Introduction: Craniopharyngioma: current and emerging treatment modalities. (27903127)
2016
18
A quantitative analysis of craniopharyngioma cyst expansion during and after radiation therapy and surgical implications. (27903114)
2016
19
Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma. (26763580)
2016
20
Erratum: Treatment options for pediatric craniopharyngioma. (27656316)
2016
21
Microsurgical removal of craniopharyngioma: endoscopic and transcranial techniques for complication avoidance. (27198571)
2016
22
Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. (26927026)
2016
23
Pediatric symptomatic Rathke cleft cyst compared with cystic craniopharyngioma. (27392448)
2016
24
When Occam's razor fails: hemipontine infarct on a background of previous surgery and radiotherapy for craniopharyngioma. (27056943)
2016
25
Endoscopic Endonasal Surgery for Purely Intra-Third Ventricle Craniopharyngioma. (27108029)
2016
26
Analysis and Long-Term Follow-Up of the Surgical Treatment of Children With Craniopharyngioma. (28005815)
2016
27
TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology. (27409178)
2016
28
Letter to the Editor: Electing the surgical approach in craniopharyngioma surgery. (27058203)
2016
29
Distinct patterns of primary and motile cilia in Rathke's cleft cysts and craniopharyngioma subtypes. (27562488)
2016
30
Early ectopic recurrence of craniopharyngioma in the cerebellopontine angle. (27593820)
2016
31
Cholesterol granulomas presenting as sellar masses: a similar, but clinically distinct entity from craniopharyngioma and Rathke's cleft cyst. (27837386)
2016
32
Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin. (27903123)
2016
33
Craniopharyngioma adherence: a comprehensive topographical categorization and outcome-related risk stratification model based on the methodical examination of 500 tumors. (27903121)
2016
34
Spontaneous malignant craniopharyngioma in an aged Wistar rat. (27559246)
2016
35
Unicystic Ameloblastomatoid Cystic Craniopharyngioma: Pathological Discussion and Clinical Significance of Cyst Formation in Adamantinomatous Craniopharyngioma. (26795029)
2016
36
Management strategy for treatment of vasospasm following transsphenoidal excision of craniopharyngioma. (27638640)
2016
37
Osteoblastic differentiation and cell calcification of adamantinomatous craniopharyngioma induced by bone morphogenetic protein-2. (27983534)
2016
38
Frontal dermoid cyst coexisting with suprasellar craniopharyngioma: a spectrum of ectodermally derived epithelial-lined cystic lesions? (27903118)
2016
39
Investigating the Role of Hypothalamic Tumor Involvement in Sleep and Cognitive Outcomes Among Children Treated for Craniopharyngioma. (27189690)
2016
40
Primary ectopic frontotemporal extradural craniopharyngioma. (27195250)
2016
41
Ectopic craniopharyngioma of the fourth ventricle in a patient with Gardner syndrome. (26995577)
2016
42
HORMONE SUBSTITUTION AFTER GASTRIC BYPASS SURGERY IN PATIENTS WITH HYPOPITUITARISM SECONDARY TO CRANIOPHARYNGIOMA. (26789341)
2016
43
Parent observed neuro-behavioral and pro-social improvements with oxytocin following surgical resection of craniopharyngioma. (27166717)
2016
44
Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma. (27161333)
2016
45
Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice. (27903120)
2016
46
Third ventricular craniopharyngioma. (27381152)
2016
47
Bypass surgery to treat symptomatic fusiform dilation of the internal carotid artery following craniopharyngioma resection: report of 2 cases. (27903112)
2016
48
Oxytocin inA survivors of childhood-onset craniopharyngioma. (27585663)
2016
49
Risk-adapted treatment and follow-up management in childhood-onset craniopharyngioma. (26982163)
2016
50
Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma. (27981514)
2016

Variations for Craniopharyngioma

About this section

Cosmic variations for Craniopharyngioma:

8 (show all 21)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM5672CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.94G>Ap.D32N6
2COSM5677CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.98C>Gp.S33C6
3COSM5679CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.110C>Gp.S37C6
4COSM5684CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.100G>Cp.G34R6
5COSM5668CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.94G>Cp.D32H6
6COSM5683CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.97T>Gp.S33A6
7COSM5663CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.133T>Cp.S45P6
8COSM5676CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.122C>Tp.T41I6
9COSM5669CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.98C>Tp.S33F6
10COSM5686CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.100G>Ap.G34R6
11COSM5661CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.94G>Tp.D32Y6
12COSM5662CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.110C>Tp.S37F6
13COSM476BRAFpituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.1799T>Ap.V600E6
14COSM5682CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.97T>Cp.S33P6
15COSM5673CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.98C>Ap.S33Y6
16COSM5664CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.121A>Gp.T41A6
17COSM5681CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.95A>Gp.D32G6
18COSM5701CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.122C>Gp.T41S6
19COSM5758CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.127G>Ap.A43T6
20COSM5687CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.109T>Cp.S37P6
21COSM5691CTNNB1pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatousc.95A>Tp.D32V0

Expression for genes affiliated with Craniopharyngioma

About this section
Search GEO for disease gene expression data for Craniopharyngioma.

GO Terms for genes affiliated with Craniopharyngioma

About this section

Cellular components related to Craniopharyngioma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cell peripheryGO:007194410.5CTNNB1, KRT14, KRT8
2secretory granule lumenGO:00347749.9GHRL, INS
3extracellular regionGO:00055768.3GHRL, GNRH1, IGF1, INS, MMP20, PRL

Biological processes related to Craniopharyngioma according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1myoblast differentiationGO:004544510.7CTNNB1, IGF1
2positive regulation of glycogen biosynthetic processGO:004572510.5IGF1, INS
3positive regulation of glycolytic processGO:004582110.5IGF1, INS
4negative regulation of feeding behaviorGO:200025210.4INS, TRH
5cellular protein metabolic processGO:004426710.3IGF1, INS, PRL
6female pregnancyGO:000756510.2GNRH1, IGF1, PRL
7cell fate specificationGO:000170810.1CTNNB1, POU1F1
8cell proliferationGO:000828310.0CTNNB1, IGF1, MKI67, PRL
9adenohypophysis developmentGO:002198410.0POU1F1, PROP1
10positive regulation of MAPK cascadeGO:00434109.8CTNNB1, IGF1, INS
11negative regulation of apoptotic processGO:00430669.4BRAF, GHRL, GNRH1, IGF1, PROP1
12somatotropin secreting cell differentiationGO:00601269.2POU1F1, PROP1

Molecular functions related to Craniopharyngioma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1insulin-like growth factor receptor bindingGO:000515910.8IGF1, INS
2hormone activityGO:00051799.7GHRL, GNRH1, IGF1, INS, PRL
3protein bindingGO:00055154.7BRAF, CTNNB1, GHRL, IGF1, INS, KRT14

Sources for Craniopharyngioma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet